FIELD: pharmaceuticals.
SUBSTANCE: invention relates to use of melflufen (melphalan flufenamide; ethyl ether of L-melphalanyl-4-fluoro-L-phenylalanine) or a pharmaceutically acceptable salt thereof for treating or preventing multiple myeloma, where the melflufen dose of 35 to 45 mg (excluding the weight of any salt) is administered in the form of a parenteral dose at infusion rate of 1.2 to 1.4 mg/min.
EFFECT: dosing regimes of melflufen for cancer diseases are proposed.
22 cl, 6 dwg, 15 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS FOR ADMINISTRATION OF 3-(4-AMINO-1-OXO-1,3-DIHYDROISOINDOLE-2-YL)PIPERIDINE-2,6-DIONE IN CERTAIN TYPES OF LEUKEMIA | 2006 |
|
RU2406501C2 |
| DOSES OF PANOBINOSTAT FOR MULTIPLE MYELOMA | 2016 |
|
RU2729425C2 |
| COMPOSITIONS AND METHODS FOR TREATING DISEASE | 2007 |
|
RU2482877C2 |
| LYOPHILIZED PREPARATIONS OF MELPHALAN FLUFENAMIDE | 2013 |
|
RU2643762C2 |
| PHARMACEUTICAL COMBINATIONS OF HISTONE DEACETYLASE INHIBITOR AND PROTEASOME INHIBITOR OR IMMUNOMODULATORY DRUG FOR TREATING BLOOD CANCER | 2017 |
|
RU2721409C1 |
| METHOD OF TREATING MULTIPLE MYELOMA | 2009 |
|
RU2519750C2 |
| METHODS AND COMPOSITIONS USING IMMUNOMODULATORY COMPOUNDS FOR TREATMENT AND MAINTENANCE OF CANCER AND OTHER DISEASES | 2004 |
|
RU2348407C2 |
| NEW SYNERGETIC EFFECTS | 2009 |
|
RU2471499C2 |
| APPLICATIONS OF IMMUNOCONJUGATES WITH CD138 AS TARGET | 2010 |
|
RU2561041C2 |
| APPLICATIONS OF IMMUNOCONJUGATES, THE TARGET OF WHICH IS CD138 | 2012 |
|
RU2632108C2 |
